Barclays PLC Regenxbio Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Barclays PLC holds 116,024 shares of RGNX stock, worth $884,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares
116,024
Previous 116,024 -0.0%
Holding current value
$884,102
Previous $1.22 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$10.49 - $14.39 $712,774 - $977,771
67,948 Added 141.33%
116,024 $1.22 Million
Q2 2024

Aug 14, 2024
SELL
$11.51 - $21.53 $15,837 - $29,625
-1,376 Reduced 2.78%
48,076 $561,000
Q1 2024

May 15, 2024
SELL
$12.17 - $24.61 $761,257 - $1.54 Million
-62,552 Reduced 55.85%
49,452 $1.04 Million
Q4 2023

Feb 15, 2024
BUY
$12.89 - $20.82 $389,239 - $628,701
30,197 Added 36.91%
112,004 $2.01 Million
Q3 2023

Nov 07, 2023
SELL
$16.46 - $19.99 $139,383 - $169,275
-8,468 Reduced 9.38%
81,807 $1.35 Million
Q2 2023

Aug 03, 2023
BUY
$17.23 - $21.71 $405,370 - $510,771
23,527 Added 35.25%
90,275 $1.8 Million
Q1 2023

May 04, 2023
SELL
$18.08 - $24.55 $539,868 - $733,063
-29,860 Reduced 30.91%
66,748 $1.26 Million
Q4 2022

Feb 13, 2023
BUY
$20.4 - $24.73 $233,845 - $283,479
11,463 Added 13.46%
96,608 $2.19 Million
Q3 2022

Nov 03, 2022
BUY
$22.29 - $35.04 $1.57 Million - $2.46 Million
70,215 Added 470.29%
85,145 $2.25 Million
Q2 2022

Aug 12, 2022
SELL
$19.35 - $35.04 $631,119 - $1.14 Million
-32,616 Reduced 68.6%
14,930 $369,000
Q1 2022

May 16, 2022
SELL
$24.62 - $34.31 $488,140 - $680,264
-19,827 Reduced 29.43%
47,546 $1.58 Million
Q4 2021

Feb 14, 2022
SELL
$30.19 - $40.28 $7,728 - $10,311
-256 Reduced 0.38%
67,373 $2.2 Million
Q3 2021

Nov 09, 2021
BUY
$29.09 - $45.68 $948,072 - $1.49 Million
32,591 Added 93.02%
67,629 $2.84 Million
Q2 2021

Aug 13, 2021
SELL
$32.46 - $40.48 $1.15 Million - $1.44 Million
-35,460 Reduced 50.3%
35,038 $1.36 Million
Q1 2021

May 13, 2021
BUY
$33.61 - $49.95 $1.01 Million - $1.5 Million
29,944 Added 73.84%
70,498 $2.41 Million
Q4 2020

Feb 11, 2021
SELL
$26.52 - $49.35 $827,821 - $1.54 Million
-31,215 Reduced 43.49%
40,554 $1.84 Million
Q3 2020

Nov 12, 2020
SELL
$27.01 - $40.26 $464,409 - $692,230
-17,194 Reduced 19.33%
71,769 $1.98 Million
Q2 2020

Aug 12, 2020
SELL
$27.75 - $43.44 $32,245 - $50,477
-1,162 Reduced 1.29%
88,963 $3.28 Million
Q1 2020

May 13, 2020
SELL
$21.5 - $54.2 $2.08 Million - $5.23 Million
-96,543 Reduced 51.72%
90,125 $2.92 Million
Q4 2019

Feb 10, 2020
BUY
$34.54 - $44.87 $4.34 Million - $5.64 Million
125,679 Added 206.07%
186,668 $7.65 Million
Q3 2019

Nov 14, 2019
SELL
$31.84 - $50.88 $232,049 - $370,813
-7,288 Reduced 10.67%
60,989 $2.17 Million
Q2 2019

Aug 14, 2019
SELL
$42.0 - $59.29 $617,484 - $871,681
-14,702 Reduced 17.72%
68,277 $3.51 Million
Q1 2019

May 15, 2019
BUY
$40.82 - $62.45 $1.96 Million - $3 Million
48,106 Added 137.95%
82,979 $4.76 Million
Q4 2018

Feb 14, 2019
BUY
$39.11 - $75.15 $44,389 - $85,295
1,135 Added 3.36%
34,873 $1.46 Million
Q3 2018

Nov 14, 2018
BUY
$65.0 - $82.15 $1.03 Million - $1.3 Million
15,860 Added 88.71%
33,738 $2.55 Million
Q2 2018

Aug 14, 2018
SELL
$27.2 - $74.35 $71,726 - $196,060
-2,637 Reduced 12.85%
17,878 $1.28 Million
Q1 2018

May 15, 2018
BUY
$24.05 - $37.5 $116,329 - $181,387
4,837 Added 30.85%
20,515 $614,000
Q4 2017

Feb 14, 2018
BUY
$26.0 - $34.6 $86,242 - $114,768
3,317 Added 26.83%
15,678 $521,000
Q3 2017

Nov 14, 2017
BUY
$18.0 - $32.95 $222,498 - $407,294
12,361
12,361 $407,000

Others Institutions Holding RGNX

# of Institutions
196
Shares Held
43M
Call Options Held
104K
Put Options Held
478K
View Full List

About REGENXBIO Inc.

RGNX Quotes by TradingView
  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email